A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-08 | actual | When the study began enrolling |
| Primary completion | 2025-07-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Chronic Liver Disease
- Healthy Participants
Interventions
- Drug: AZD2389
- Drug: Midazolam
- Drug: Caffeine
- Drug: Bupropion
Primary outcomes
what the primary-completion date above is the date OFRatio of treatment to reference based on Cmax (RCmax)
measured Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
Ratio of treatment to reference based on AUCinf (RAUCinf)
measured Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
Ratio of treatment to reference based on AUClast (RAUClast)
measured Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
Ratio of area under concentration-curve from time 0 to 24 hours post-dose (AUC0-24)
measured Period 1: Days 1-3; Period 3: Days 15-18.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed